Last updated 3rd May 2021
We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
At this unprecedented time, we are actively managing our global supply chains to minimise potential disruption, and we are monitoring the situation closely. We will put the needs of patients first at all times.
At present, with the exception of specific supply disruptions as outlined below, we have adequate stock in place in Australia.
Duac Once Daily Gel clindamycin (as phosphate) 1% and benzoyl peroxide 5% topical gel tube
Due to ongoing supply issues, Duac is currently unavailable. We expect this shortage to be resolved by the end of May 2021. Please consult your healthcare professional should you require an alternative.
Kozenis (Tafenoquine) a medicine used to treat infection with Plasmodium vivax malaria, will be unavailable from late April, 2021 until November, 2021 when it is resupplied. Alternate medicines continue to be available, and we do not anticipate there to be a major impact to patients.
GSK is anticipating a shortage of Varilrix (live varicella vaccine) in the private market from early June 2021 until mid-September 2021. We are currently working on ways to expedite shipments to Australia, and in the meantime, we understand that an alternate varicella vaccine remains available in the private market. We do not anticipate significant impacts for patients. For further questions, please contact your healthcare provider.
- VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose
- VENTOLIN INHALER CFC-Free Salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose (with counter)
From August 2020, an updated Ventolin (salbutamol) inhaler with a dose counter will be introduced gradually over a period of four to six months, while existing stock of VENTOLIN (without dose counter) continues to be sold in pharmacies.
While Australians may see limited availability of VENTOLIN with dose counter in the early months, the full transition is expected to be complete by early 2021. After this time, all VENTOLIN inhalers available will have a dose counter.
The inhaler with dose counter operates the same way for patients and contains the same medication and same dose. The only change is the integration of a dose counter which will allow patients to view the number of doses remaining in their inhalers.
The transition to the Ventolin (salbutamol) inhaler with dose counter is not expected to impact supply, though we continue to closely monitor the continuing peaks in demand which have occurred in the first half of 2020.
We maintain good stock levels of Ventolin inhalers, however we will continue to monitor the situation to ensure supplies are distributed to where they are needed. Unprecedented and unpredictable high consumer demand for Ventolin (salbutamol) inhalers across Australia in the first half of 2020 may still periodically impact availability in some areas of the country at a pharmacy level.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.